Shanxi Teamgene Biological announced that it will receive CNY 50,000,000 in a round of funding on March 30, 2023. The transaction included participation from returning investor Shandong Teamgene Technology Co., Ltd. After the capital increase, company's registered capital will increase from CNY 115,000,000 to CNY 165,000,000 still the company's wholly-owned subsidiary. The transaction has been approved in the 13th session of the company's 1st directorate and the 11th session of the company's 1st supervisory board approved.